Insmed’s (INSM) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Insmed (NASDAQ:INSM)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a report issued on Wednesday,Benzinga reports.

A number of other brokerages have also recently commented on INSM. Wells Fargo & Company lifted their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Guggenheim lifted their target price on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday, February 7th. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. Finally, Morgan Stanley boosted their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $90.86.

Insmed Stock Down 0.3 %

INSM stock opened at $83.61 on Wednesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed has a twelve month low of $21.92 and a twelve month high of $84.28. The company’s 50 day moving average is $74.11 and its two-hundred day moving average is $73.52. The stock has a market cap of $14.96 billion, a P/E ratio of -15.06 and a beta of 1.11.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Research analysts expect that Insmed will post -5.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insmed news, insider Martina M.D. Flammer sold 3,344 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now directly owns 102,766 shares in the company, valued at approximately $6,773,307.06. The trade was a 3.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the sale, the chief executive officer now owns 384,960 shares in the company, valued at $26,912,553.60. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 532,207 shares of company stock worth $41,400,465. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after buying an additional 1,075,796 shares in the last quarter. Darwin Global Management Ltd. boosted its position in shares of Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after buying an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Insmed by 1.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock worth $877,113,000 after buying an additional 123,429 shares in the last quarter. Capital International Investors boosted its position in shares of Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after buying an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after buying an additional 273,759 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.